PainReform Ltd. - Ordinary Shares (PRFX)

Frequently Asked Questions About PainReform Ltd. - Ordinary Shares (PRFX)

How does PainReform address the issues of opioid addiction?

PainReform addresses the issues of opioid addiction by providing alternative pain management therapies that are designed to offer effective relief without the risk of dependence associated with traditional opioid medications. The company's focus on developing non-opioid pain relief options is crucial in the fight against the opioid crisis.

How does PainReform approach research and development?

PainReform approaches research and development with a rigorous methodology, focusing on scientific innovation and clinical validation. The company invests in comprehensive studies that explore the efficacy, safety, and quality of its product candidates to meet the highest industry standards.

How does PainReform engage with investors?

PainReform engages with investors through regular updates on clinical trial progress, financial performance, and strategic initiatives. The company participates in investor conferences and provides opportunities for direct communication, ensuring transparency and fostering investor confidence.

Is PainReform involved in any partnerships?

Yes, PainReform is involved in various partnerships to enhance its research capabilities and expedite the development of its product pipeline. Collaborations with universities, research institutes, and other biopharmaceutical companies are integral to fostering innovation and commercialization.

What are PainReform's growth strategies?

PainReform's growth strategies include advancing its product candidates through clinical trials, obtaining regulatory approvals, and pursuing strategic partnerships with other pharmaceutical companies. The company aims to commercialize its innovative pain management solutions to address unmet needs in the market.

What are the potential applications for PRF-110?

PRF-110 has potential applications in various surgical procedures where effective pain management is critical, including orthopedic surgery, dental procedures, and outpatient surgeries. Its prolonged pain relief mechanism could significantly enhance patient recovery experiences.

What are the potential side effects of PRF-110?

As with any medical treatment, potential side effects of PRF-110 may include localized irritation or adverse reactions at the injection site. However, extensive clinical trials are conducted to assess the safety profile of the product and minimize risks associated with its use.

What can investors expect from PainReform in the next few years?

Investors can expect PainReform to continue advancing its product pipeline, with potential milestones in clinical development and regulatory submissions in the coming years. The company is committed to delivering value for its shareholders while transforming the landscape of pain management.

What challenges does PainReform currently face?

Like many biopharmaceutical companies, PainReform faces challenges such as navigating complex regulatory environments, securing funding, and competing in a dynamic market. Addressing these challenges effectively is essential for the company’s ongoing growth and success.

What distinguishes PainReform from other pharmaceutical companies?

PainReform distinguishes itself through its specialized focus on pain management, combined with a commitment to developing unique drug delivery technologies. The emphasis on non-opioid solutions and sustainable pain relief sets PainReform apart in a competitive market.

What does PainReform Ltd. do?

PainReform Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for pain management. The company specializes in providing long-lasting pain relief solutions through its proprietary formulations that target various types of acute and chronic pain.

What is PainReform's vision for the future?

PainReform's vision for the future includes becoming a leader in the field of pain management by providing groundbreaking therapies that improve patient outcomes. The company aims to expand its product portfolio and reach new markets globally, addressing the persistent challenges of pain management.

What is the importance of regulatory approval for PainReform?

Regulatory approval is critical for PainReform as it validates the safety and efficacy of its products, enabling the company to bring its therapies to market. Achieving regulatory milestones allows PainReform to generate revenue and fulfill its commitment to patients in need of effective pain relief.

What is the main product of PainReform?

PainReform's lead product candidate is PRF-110, a reformulated version of an existing local anesthetic that is designed to provide sustained pain relief for patients undergoing surgical procedures. It leverages a proprietary delivery system to extend the duration of pain relief beyond the standard duration typically provided by conventional anesthetics.

What is the significance of PainReform's technology?

The significance of PainReform's technology lies in its potential to provide patients with longer-lasting pain relief while minimizing the need for opioids and reducing associated side effects. This innovation addresses growing concerns about opioid dependency and opens new avenues for effective pain management.

What recent developments has PainReform announced?

PainReform has announced the successful completion of key clinical trials demonstrating the efficacy and safety of its lead product candidate, PRF-110. Additionally, the company is actively working on preparing regulatory submissions to gain market approval and expand its product offerings.

When did PainReform go public?

PainReform Ltd. went public on the NASDAQ stock exchange in December 2020. This move was aimed at raising capital to support the further development of its product pipeline and enhance its growth potential in the biopharmaceutical sector.

Where is PainReform Ltd. headquartered?

PainReform Ltd. is headquartered in Tel Aviv, Israel. The strategic location allows the company to be part of a vibrant biotech ecosystem and collaborate with various research institutions and healthcare providers.

Who are the key members of PainReform's management team?

PainReform's management team comprises experienced professionals from the pharmaceutical and biotechnology sectors, including experts in drug development, regulatory affairs, and commercial operations. Their collective expertise drives the company's mission to deliver innovative pain management solutions.

What is the current price of PainReform Ltd. - Ordinary Shares?

The current price of PainReform Ltd. - Ordinary Shares is 2.300

When was PainReform Ltd. - Ordinary Shares last traded?

The last trade of PainReform Ltd. - Ordinary Shares was at 3:59 pm EDT on April 2nd, 2025